ABSTRACT
INTRODUCTION
Human papillomavirus (HPV) infection is one of the most common sexually transmitted infections worldwide. 1 In both men and women, persistent infection with high-risk types of HPV (hrHPV) is associated with anogenital and oropharyngeal cancers, whereas low-risk HPV (lrHPV) types can cause genital warts. 2 The prevalence of genital HPV infections in men ranges widely (1.3-72.9%) 3, 4 depending on population and sampled anatomical site. 5 A recent meta-analysis has revealed that HPV is commonly present in semen samples, with an estimated prevalence of 16% in infertile populations and 10% in men from the general population. 6 Data on the underlying source of the presence of HPV in semen are very limited. We have recently found an association between HPV infection of the penile epithelium and the presence of HPV in semen, suggesting that HPV presence in semen might result from exfoliation of HPV-infected penile keratinocytes. 7 A remaining question to be answered is whether the presence of HPV in semen is associated with impairment of male fertility. This knowledge can be valuable for guidelines on the possible necessity of HPV testing in the diagnostic work-up for subfertile couples and in procedures of assisted reproduction.
So far, conflicting results have been reported. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Most previous studies on this topic have been performed on relatively small cohorts. 16, 17 In the current study, we investigated the relation of seminal HPV presence with semen parameters in a large cohort of 430 male partners of couples seeking fertility evaluation.
METHODS

Study population
Study participants were recruited among male attendants of the fertility clinic of VU University
Medical Center in Amsterdam, the Netherlands. According to national Dutch guidelines, couples who seek fertility evaluation because of an inability to conceive after ≥1 year of regular sexual intercourse are offered a diagnostic work-up which includes a basic semen analysis. Between
September 2012 and January 2014, all male attendants providing a semen sample at VU University
Medical Center for such primary fertility evaluation were asked to provide written consent for anonymous additional testing of their semen sample. Men with a history of vasectomy or testicular cancer were excluded from participation.
Ethical approval
As semen samples were collected in routine diagnostics, handled anonymously and additional tests were performed on residual material only, no Institutional Review Board approval was required for this study, in concordance with Dutch legislation and the Dutch code of conduct on responsible use of human tissue for research (2011).
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Semen collection and analysis
Men were advised to have sexual abstinence three days prior to semen donation. The actual duration of sexual abstinence was self-reported by the participants. Following masturbation, semen samples were collected directly into a 100-ml polystyrene container (Sterilin, UK). Semen samples were analyzed within one hour after ejaculation. Basic semen analysis was based on WHO guidelines 19 with the exceptions that semen volume was measured in a graded pipette with a 0.1-ml accuracy (after liquefaction), sperm concentration was counted and motility was assessed in a
Makler counting chamber at a magnification of ×200. The presence of anti-sperm antibodies was assessed by a mixed agglutination reaction (MAR)-test using IgG coated red blood cells (Checkcell,
Immucor, USA) and N antiserum for human IgG (Siemens Healthcare Diagnostics, Germany). All assessments were performed by trained laboratory technicians who were blinded for HPV test results.
HPV DNA detection and genotyping
After performance of basic semen analysis, the remaining semen sample was suspended in 10 ml PreservCyt medium (Hologic, USA) and stored at room temperature until further processing.
Three ml aliquots of resuspended semen samples were used for DNA isolation. After automated DNA isolation using Macherey-Nagel magnetic beads and a Hamilton Star liquid handler (Hamilton Robotics, USA), DNA was subjected to GP5+/6+-PCR with enzyme immunoassay (EIA) read-out using cocktail probes for lrHPV and hrHPV types, respectively (Diassay B.V., the Netherlands) 20 and subsequent microsphere bead-based genotyping 21 . For DNA quality control, a beta-globin-PCR was performed on all samples. Specimens testing negative in both HPV-and beta-globin-PCR assays were considered invalid and therefore excluded from analyses. Samples were considered 'overall HPV-positive' when they tested positive for either hrHPV or lrHPV type(s), and HPVnegative when they tested negative for both hrHPV and lrHPV types. Samples that were EIA-positive but in which no genotypes could be detected were considered to contain uncharacterized types, referred to as HPV type X.
Statistical analysis
Estimating the HPV prevalence in semen in a cohort of men attending a fertility clinic to be around 16%, 6 we calculated that we would be able to detect a difference in progressive sperm motility between HPV-positive and HPV-negative semen samples of at least 8% with a power of 80% by including a minimum of 354 men (two-sided α=0.05).
HPV positivity rates were calculated with 95% confidence intervals (CI) using the Wilson score method. In HPV-positive semen samples, the prevalence of separate HPV genotypes was 
RESULTS
After written consent, a total of 431 participants provided one semen sample per person. One semen sample had inadequate sample quality for HPV testing and was therefore excluded from analyses.
The mean age of the resulting 430 men was 36.2 years (CI 35.6-36.8). HPV positivity rates in semen are summarized in Table 1 . Overall HPV positivity in the total study population was 14.9%
(64/430; CI 11.8-18.6%). In 2.1% (9/430; CI 1.1-3.9%) of samples both hrHPV and lrHPV types were detected. In 8.8% (38/430; CI 6.5-11.9%) of samples exclusively hrHPV types were present, and 4.0% (17/430; 2.5-6.2%) of samples contained exclusively lrHPV types. The presence of overall HPV in semen was not related with the age of the participants; nor was the presence of hrHPV or lrHPV (separately or in combination).
In the majority of HPV-positive semen samples, a single HPV-type was detected (47/64; 73.4%; CI 61.5-82.7%). Genotype distribution is shown in Table 3 shows participant characteristics and semen parameters in the total study population and in strata of seminal HPV presence, including an overall comparison between all HPVsubgroups. Comparisons of different HPV-positive subgroups with HPV-negative samples (as a control group) are shown in Table 4 . The duration of sexual abstinence differed significantly between all HPV-subgroups (p=0.025; Table 3 ) and between the overall HPV-positive group and HPV-negative group (p<0.001; Table 4 Table 4 ). Secondly, the semen volume differed significantly between all HPVsubgroups (p=0.039; Table 3 ). Semen samples that tested exclusively hrHPV-positive had a mean volume of 2.9 ml, which was significantly lower than that of HPV-negative samples (3. Table 4 ). 
DISCUSSION
In this large cohort, comprising male partners of couples seeking fertility evaluation, we confirmed that HPV-DNA is commonly present in semen. We could not demonstrate any association between the presence of HPV in semen and semen parameters.
To our knowledge, this is the second largest study assessing seminal HPV presence in relation to semen parameters. 16, 17 We detected an overall HPV prevalence of 14.9%, which is in accordance with a recent meta-analysis 6 describing a pooled prevalence of 16% in fertility clinic attendees. We recently showed that Dutch healthy volunteers had a markedly higher seminal HPV prevalence of 27%, which might be explained by the age difference between populations (36 years in the present cohort in contrast to 22 years in the healthy volunteers). Other studies in asymptomatic men (students, fathers-to-be) have reported prevalences of HPV in semen ranging from 2% to 31%, 9, 12, 15 and estimates in semen donors were 16% to 26%. 22, 23 As recently outlined in two systematic reviews, 16, 17 previous studies on semen parameters in relation to seminal HPV presence have shown conflicting results. The majority of published studies (which were performed in different types of populations and had a total sample size of 1944 participants) 16 described a reduced sperm motility in HPV-positive samples. This association could however not be confirmed in three studies (of which one was performed in fathers-to-be, and two in men seeking fertility evaluation) [13] [14] [15] and the present study, all together representing 1143 participants.
In the present study, semen analysis (which is in part a subjective analysis, such as the ranking of sperm cell motility) was performed by technicians who were blinded for HPV-test results.
Limitations of our study include the absence of data on sperm morphology, which was not tested in each primary semen analysis, but performed only on physician's request. Secondly, MAR-testing was performed for IgG only.
Although binding sites on sperm for IgG and IgA have been shown to be highly concordant, 24 we might have underestimated the number of samples with anti-sperm antibodies (both in HPVpositive and HPV-negative samples).
In a previous study, we have found that the presence of HPV in semen is closely related to HPV infections of the penile epithelium, even on a genotype-specific level. 7 The current findings, demonstrating that HPV presence in semen is not associated with an impairment of semen function, are in line with the suggestion that HPV presence in semen does not necessarily affect spermatozoa but is rather a side-effect of desquamation of HPV-infected penile keratinocytes. 7 Current guidelines for assisted reproductive technologies 25, 26 do not include the screening of semen for presence of HPV-DNA. As proposed previously, 7 screening of donor semen for HPV may be considered to prevent unnecessary viral transmission to the female genital tract (and thereby increasing the risk of 'iatrogenic' development of cervical premalignant lesions). Donors with HPV-positive semen could be followed-up and re-invited to donate after viral clearance
(within approximately seven months). 27 Recently, researchers have also suggested standardized HPV testing on semen for diagnostic purposes in unexplained infertility 16 and prior to procedures of assisted reproduction. 16, 17 However, so far only two studies have addressed whether men with HPV-positive semen have altered clinical reproductive outcomes when compared to men with HPV-negative semen. 28, 29 Perino et al. observed that seminal HPV positivity was not associated to pregnancy rates but might be related to the occurrence of spontaneous abortions. 28 Recently, using fluorescence in situ hybridization (FISH) for HPV detection, Garolla et al. described a decreased conception rate and an increased miscarriage rate in couples with HPV-positive semen. 29 The presence of HPV-DNA was described in products of conception in both spontaneous and voluntary abortions, 30, 31 as well as in placentas at term. 32 In vitro and animal studies have shown negative effects of semen-transferred HPV on embryonic development 33 washing technique using a modified swim-up with enzymatic treatment 11 has shown promising results for the elimination of HPV from semen, but should be more extensively studied.
In conclusion, this study confirmed earlier findings that HPV-DNA is commonly present in semen of men seeking fertility evaluation. However, no association of seminal HPV presence with semen parameters was observed. Therefore, screening for HPV in semen should currently only be considered for donor semen to prevent unnecessary viral transmission to the female genital tract, but not for diagnostic settings in assisted reproduction. Further large studies are needed to elucidate the clinical relevance of HPV presence in semen by focusing on conception, early embryo development and clinical reproductive outcomes.
